Panda oocyte in-vitro maturation culture solution and application thereof
By adding ARF6, CNTF, and HGF to the in vitro maturation culture medium of giant panda oocytes, the problems of uncoordinated oocyte maturation and insufficient in vitro culture system were solved, achieving efficient and safe multi-target synergistic regulation and improving the maturation rate and quality of giant panda oocytes.
Patent Information
- Application Number
- CN202610622251.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-05-08
- Publication Date
- 2026-06-02
AI Technical Summary
Existing in vitro oocyte maturation technologies suffer from incoordination and asynchronous maturation between nuclear and cytoplasmic maturation, making it difficult to simulate the in vivo microenvironment and lacking efficient and safe paracrine factor supplementation strategies. This results in low maturation rates, low embryo development rates, and poor quality, especially for rare and endangered species such as giant pandas, where there is a lack of effective culture systems.
By adding specific concentrations of paracrine factors ARF6, CNTF, and HGF to the basal culture medium, the maturation microenvironment of oocytes in vivo was simulated. Through multi-target synergistic regulation, the nuclear maturation rate and cytoplasmic maturation quality were improved, aging and apoptosis were reduced, and developmental potential was enhanced.
It significantly improves the maturation rate and quality of oocytes, enhances cumulus cell expansion, reduces aging and apoptosis, and improves developmental potential. It simplifies the operation and has high safety, making it suitable for in vitro maturation culture of giant panda oocytes.